| Project/Area Number |
18K17232
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 57060:Surgical dentistry-related
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
BABA Junichi 横浜市立大学, 附属病院, 助教 (40644539)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 口腔扁平上皮癌 / aPKCλ/ι / OSCC |
|---|
| Outline of Final Research Achievements |
Atypical protein kinase C λ/ι (aPKCλ/ι) is a cell polarity-regulator localized in the tight junction and apical membrane in epithelial cells. Previous studies suggested that aPKCλ/ι overexpression and abnormal localization were involved in tumor progression in several cancers. We investigated the relationship between aPKCλ/ι and oral squamous cell carcinoma (OSCC).
The correlation between the aPKCλ/ι expression and the clinicopathological parameters was examined using immunohistochemical analyses. In result, aPKCλ/ι expression was more intense in poorly differentiated OSCC and younger patients. Although expression of aPKCλ/ι was not significantly associated with clinical parameters, the correlation was found between aPKCλ/ι localization and progression-free survival. This is the first study to assess the association of aPKCλ/ι expression in OSCC with clinical results. Expression and localization of aPKCλ/ι may be involved in the degree of malignancy in OSCC.
|
| Academic Significance and Societal Importance of the Research Achievements |
口腔扁平上皮癌では低分化型ほど予後が悪いとされている．今回の研究では，低分化型においてaPKCλ/ιの過剰発現を認めたことから，aPKCλ/ιの過剰発現が予後予測因子となり得る可能性が示唆された．また，aPKCλ/ιの細胞局在が核優位になると5年累積無増悪生存率が低下したため，aPKCλ/ιの細胞局在は重要な予後予測因子になることが示唆された．口腔がんにおいては特異的な診断マーカーが存在しておらず，aPKCλ/ιが有用な診断マーカーとなり得る可能性，さらにはをaPKCλ/ιをターゲットとした新たな分子標的薬開発にも繋がる可能性がある．
|
